ArticleThe Lancet. Oncology2018
Lorlatinib: a new-generation drug for ALK-positive NSCLC.
Saiama N Waqar et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5 papers cite it
this papercites it
ArticleThe Lancet. Oncology2018
Saiama N Waqar et al.PubMed ↗Publisher ↗
No numbers read from the abstract.